RxDoctor Payments Data

Gary Hoss, MD

Internal Medicine · Garland, TXNPI 1083642714

Payments from drug & device makers

$333in general payments, 2019–2025

Across 20 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$101
  • Dexcom, Inc.$69
  • AbbVie$37
  • AstraZeneca$36
  • Novartis$21
  • Lilly USA, LLC$21
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$333100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$333 in reported general payments places this provider in the 50th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$201,683
Medicare patients
584
Services billed
2,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide174$250,455
JardianceEmpagliflozin133$181,681
EliquisApixaban74$77,293
FarxigaDapagliflozin Propanediol62$58,172
XareltoRivaroxaban35$51,838
JanuviaSitagliptin Phosphate39$41,876
Tresiba Flextouch U-100Insulin Degludec40$41,050
MounjaroTirzepatide17$29,954
Tresiba Flextouch U-200Insulin Degludec13$27,930
Lantus SolostarInsulin Glargine,hum.Rec.Anlog95$16,724
JanumetSitagliptin Phos/Metformin Hcl16$16,364
LinzessLinaclotide16$15,273
Humalog Kwikpen U-100Insulin Lispro31$12,179
Novolog FlexpenInsulin Aspart42$11,301
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp12$9,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$101$250,455174 claims
AstraZenecaFarxiga$36$58,17262 claims
Lilly USA, LLCMounjaro$21$29,95417 claims
AbbVieLinzess, Synthroid$37$19,99984 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Garland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →